ZUGA Medical, a Rising Star in Digital Dental Implant Solutions, Secures Tens of Millions in Series B+ Funding and Files for IPO

Big data, artificial intelligence, cloud computing, machine learning... The rapid development of new technologies continues to drive swift progress and industrial transformation across various sectors. As an essential industry, healthcare has maintained steady growth. Companies with patented technologies, comprehensive product portfolios, and strong operational performance have attracted significant attention from investors.

VCBeat (WeChat ID: vcbeat) has learned that Zuga Medical recently announced the completion of its Series B+ financing round, raising tens of millions of RMB. The lead investor was the Sichuan Provincial Health and Elderly Care Fund, with co-investors including Sichuan Venture Capital, Shanghai Chuangrui, and Shengding Investment.

According to available information, Zuga Medical is an innovative medical technology company specializing in digital dental solutions. Its product portfolio encompasses digital design and manufacturing, personalized chairside equipment and services, various high-value consumables, patented applications, and mobile internet software. The company is positioned to deliver more precise, minimally invasive, and convenient digital dental solutions for both dentists and patients.

In 2009, Zuga Medical established its global headquarters in Ohio, USA. In 2015, the company rooted itself in Beijing, and in 2018, it founded its Global Digital Design Center in Chengdu. This signifies that technologies developed in China will no longer be confined to serving the domestic market but will expand globally, delivering digital R&D, design, and professional services to dentists across Asia, Europe, and the Americas.

Since its inception, Zuga Medical has secured six global patented inventions and filed seven international patent applications. Its outstanding innovations and inventive technologies have garnered investment and support from the U.S. GLIDE Innovation Fund, the North Shore Opportunity Fund, the Cleveland-NASA Invention Fund, and Sequoia Capital.

Regarding this new round of financing, Zhang Dafeng, General Manager of the Sichuan Health and Elderly Care Fund, stated: “The Chinese dental market is growing rapidly, but remains constrained by an insufficient supply of dental implant specialists. The integration of the ZUGA implant system with its digital platform lowers the barriers to implant procedures and effectively mitigates surgical risks. We believe that ZUGA will deliver superior products and services to dentists and patients alike.”

Shu Xiao, Partner at Shengding Investment, stated: “As a new entrant in the dental implant market, Zuga Medical demonstrates profound and unique insights into competition and strategic positioning within the dental industry. Positioning its products in the mid-to-high-end segment and leveraging digital innovation as a key breakthrough, the company has gained widespread recognition. This investment will primarily support Zuga Medical’s sales market expansion and the promotion of its ZUGALINK digital platform.”

Dr. Wang Qian, a Chinese scientist and co-founder of Zuga Medical, stated: “Zuga was not born merely to export technology; rather, it is dedicated to rooting new technologies in China’s dental industry, allowing them to grow, develop, and flourish on this soil. Since the establishment of Zuga Medical’s Global Digital Center in Chengdu in March 2018, the company has filed four global patents. The new funding will be used to promote the application of these technologies in real-world clinical settings, enabling both dentists and patients to benefit from the advancement of digital dentistry.”

The formal introduction of digital technologies—such as digital dental products, software, and cloud platforms—from the United States into China, followed by their expansion from China to the global market, represents Zuga Medical’s new strategic objective and industrial layout logic.

In the field of dental implantology, digitization has become a prevailing trend. Following rapid advancements in digital technology, clinicians can now leverage professional computer-aided design (CAD) software for preoperative diagnosis and precise treatment planning. As an increasing number of practitioners recognize the value of such digital solutions, the ZUGALINK platform has been launched to meet this growing demand.

ZUGALINK is a digital cloud platform launched by Zuga Medical, integrating modules for dental cloud services, implants, prosthodontics, and orthodontics. It combines functionalities such as technology sharing, order management, and expert consultation, with a strategic focus on the digital dentistry markets in both China and the United States.

In terms of specific functionalities, the ZUGALINK implant service platform offers advantages such as online treatment plan reviews by renowned experts, compatibility with all implant systems, and free design plans for ZUGA implants. By leveraging an efficient digital workflow to meet clinicians’ needs, it provides not only professional support but also helps enhance physicians’ trustworthiness in the eyes of their patients.

In addition to ZUGALINK, Zuga’s flagship offerings include a digital implant system that integrates the advantages of various implant manufacturers’ products. This has led to the development of the Jingjie System, the Jingying System, and the Surgical Guide System, which together address over 90% of the implant needs in the market. Most of these products have currently obtained FDA and CFDA certifications. In terms of product and technology, Zuga is at the forefront of digital dentistry.

Dr. Wang Qian, a Chinese-American scientist and co-founder of Zuga Medical, stated, “The entire dental industry is currently experiencing rapid development, yet many irregular practices persist, and numerous risks during surgical procedures still need to be mitigated. Digitalization represents the most effective means of risk mitigation. All our investors across various funding rounds are optimistic about the future of digital dentistry and believe in the significant impact that innovative technologies will bring to the industry. In the future, chairside digitalization and standardized surgical protocols will enable more precise and minimally invasive procedures, thereby providing greater convenience and benefits to both clinicians and patients.”

Following this round of financing, the new funds will be primarily allocated to the development and promotion of new products, increased investment in digital centers, and collaboration with clinics across various regions to establish multiple digital chairside centers nationwide. Additionally, the company will expand its bone product portfolio and enhance its patented offerings within the digital product chain. These innovations, fully grounded in digital principles, include Zuga’s proprietary OIR (Osteotomy-Implant-Restoration) triple-guide system, intelligent jaw ridges, Zuga radiographic markers, and custom smart veneer applicators.

Zuga Medical is committed to building a world-class dental digital innovation technology company and serving as an industry driver of advanced dental technologies.

The following are the investors:

Sichuan Provincial Health and Elderly Care Industry Equity Investment Fund (“Sichuan Provincial Health and Elderly Care Fund”) is a provincial-level industrial development guidance fund approved by the Sichuan Provincial People’s Government, dedicated to investing in the healthcare and wellness sector. The fund’s primary investment areas include the elderly care industry, pharmaceuticals and biotechnology, medical devices, and healthcare services.

The fund was established in December 2015. Since its inception, it has consistently adhered to the principle of “government guidance and market-oriented operations.” While fulfilling its functions in industrial guidance and support, the fund has actively promoted the integration of investment with attraction initiatives and the linkage between investment and lending, thereby assisting enterprises by providing value-added services across the entire industry chain.

In recent years, the Sichuan Provincial Health and Elderly Care Fund has invested in outstanding enterprises in the healthcare and wellness sector, including Jinxin Fertility (1951.HK), Zhenghexiang Pharmaceutical, Beite Pharmaceutical, Aixing Biology, Meibei, Konite Technology, and Hangzhou Dental Hospital Group.

Sichuan Innovation Development Investment Management Co., Ltd. (“Chuangtouzi”) focuses on investing in high-tech enterprises with independent innovation capabilities, emerging industry enterprises, and enterprises undergoing transformation and upgrading. Its investment scope covers key industries such as biopharmaceuticals, TMT, and high-end intelligent manufacturing.

Sichuan Venture Capital has currently undertaken the management of multiple provincial-level funds led by the Sichuan Provincial Government, including the Sichuan Province Innovation and Entrepreneurship Investment Guidance Fund, the Sichuan Province Scientific and Technological Achievement Transformation Investment Fund, and the Sichuan Province High-Level Talent Investment Fund. It has initially established an investment and service network deeply rooted in Sichuan and covering China.

Sichuan Venture Capital was honored with the “Top 10 Emerging Venture Capital Firms in China for 2016” and the “Top 3 Best Emerging Investment Firms in China’s Advanced Manufacturing and High-Tech Industries for 2017.” The Sichuan Provincial Innovation and Entrepreneurship Investment Guidance Fund, entrusted to Sichuan Venture Capital for management, was awarded the “Top 10 Best Venture Capital Guidance Funds in China for 2017” and “Top 10 Best Venture Capital Guidance Funds in China for 2018” by CVSource, as well as the “Top 10 Best Venture Capital Guidance Funds in China for 2017” by Financing China.

Shanghai Chuangrui Investment Group, founded in 2006, is one of the most dynamic private equity firms and advanced healthcare industry incubation platforms in China’s domestic capital market. It is committed to investing in global high-end medical technologies, upholding the core philosophy of leading the upgrading of China’s healthcare industry.

Chuangrui Fund manages assets exceeding RMB 3 billion and has invested in nearly 40 companies both domestically and internationally. As of December 2018, seven portfolio companies had successfully gone public, seven were queued for listing review, and the fund had established partnerships with four renowned Chinese medical universities and schools to jointly build official platforms for the commercialization of scientific and technological achievements.

With years of investment and advisory experience in China’s capital markets, Chuangrui Investment has successfully assisted 40 companies in securing over RMB 10 billion in funding from major venture capital firms, and has helped numerous enterprises initiate their IPO processes or achieve successful public listings. Chuangxinghui is an entrepreneurs’ club established by Chuangrui, currently boasting more than 3,000 entrepreneur partners.

Shengding Pharmaceutical Investment is a professional venture capital firm with a strong background in the healthcare industry, dedicated to investing in and incubating the most promising healthcare startups in China and overseas. Leveraging its extensive research and operational expertise in biotechnology, the Shengding investment team actively assists portfolio companies in refining their operational strategies and facilitating strategic partnerships. These efforts include the introduction of new products and technology platforms, recruitment of core talent, and cross-border collaborations, thereby enabling healthy and rapid growth for these startups as they emerge as the next generation of leaders in the healthcare industries both in China and abroad.

Shengding Pharmaceutical Investment focuses on projects from the startup to growth stages, covering areas such as new medical technologies, medical devices, new drug R&D, cell therapy, and SMO services. Its current investment portfolio includes outstanding companies such as SiMai Network, Kerui Gene, Refuge Biotech, and Ganyi Bio.